Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Combatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr Chakravarthy

Inhaled anesthetics are fairly common all over the world for minor and extensive surgical procedures in patients of all age groups. In the olden days when anesthesia was first developed, ether was the first inhaled anesthetic. That has been replaced, with the more recent discoveries of sevoflurane, isoflurane, and desflurane.

9 Nov 2015

Vanderbilt wins NIA grant to study effectiveness of nicotine patch in improving memory loss in older adults with MCI

Vanderbilt University Medical Center has received a $9.4 million grant from the National Institute on Aging to test the effectiveness of a transdermal nicotine patch in improving memory loss in older adults with mild cognitive impairment (MCI), a precursor to Alzheimer's disease.

6 Nov 2015

Genvoya approved as complete regimen for HIV treatment

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

6 Nov 2015

Researchers track re-emergence of scarlet fever-causing bacteria

An international study led by University of Queensland researchers has tracked the re-emergence of a childhood disease which had largely disappeared over the past 100 years.

4 Nov 2015

Novel enzyme therapy offers possible treatment for cocaine overdose

A long-acting enzyme that rapidly and safely metabolizes cocaine in the blood stream is currently being investigated in animal models as a possible treatment for cocaine overdose.

30 Oct 2015

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.

30 Oct 2015

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

The U.S. Food and Drug Administration announced on Oct. 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the United States. The drug was approved for use against late-stage melanoma, a deadly skin cancer that can be difficult to treat.

29 Oct 2015

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery.

29 Oct 2015

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

28 Oct 2015

Imlygic approved for treatment of melanoma lesions in the skin and lymph nodes

The U.S. Food and Drug Administration today approved Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the treatment of melanoma lesions in the skin and lymph nodes.

28 Oct 2015

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic).

24 Oct 2015

Strensiq approved for treatment of patients with juvenile-onset HPP

Today, the U.S. Food and Drug Administration approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP).

24 Oct 2015

Amgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma

Amgen today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion recommending that IMLYGIC (talimogene laherparepvec) be granted approval for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.

23 Oct 2015

New combination treatment approved by FDA for metastatic pancreatic cancer

The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.

23 Oct 2015

Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

The U.S. Food and Drug Administration today approved Veltassa (patiromer for oral suspension) to treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.

22 Oct 2015

Chemotherapy-induced nausea and vomiting most common distressing symptoms in majority of cancer patients

Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc., found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live.

20 Oct 2015

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21.

20 Oct 2015

Sprout announces U.S. availability of Addyi for HSDD treatment in premenopausal women

Sprout Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC, announced today that Addyi, a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now available in the United States through certified physicians and pharmacies.

19 Oct 2015

New breakthrough advances our understanding of how brain detects, prevents dehydration

Scientists at the Research Institute of the McGill University Health Centre (RI-MUHC) and Duke University have made a breakthrough that advances our understanding of how the brain detects and prevents dehydration.

16 Oct 2015

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that Synjardy (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States.

14 Oct 2015